DossierENTITY

survodutide

Coverage of survodutide in the Nexus archive.

Earliest in view: Jun 7 · 18:30 UTCMost recent: Jun 7 · 18:30 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 7 · 18:30 UTCSTAT NEWS
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.